Basic aspects of inhibitors to factors VIII and IX and the influence of non‐genetic risk factors

Abstract excerpt

The appearance of polyclonal antibodies inhibiting the function of exogenous factors VIII (FVIII) and IX (FIX) continues to be a major challenge in the treatment of patients with congenital haemophilia. Why these inhibitors develop in 10-20% of patients with haemophilia A, and in 1-5% of patients with haemophilia B, remains largely unexplained. The antibodies, however, are characterized by several features that...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Blood Coagulation and Thrombosis Mechanisms
• Share to Coagulation, Bradykinin, Polyphosphates, and Angioedema
• Share to Hemophilia Treatment and Research